

Mata uang kripto ini tidak di list untuk perdagangan atau layanan di Gate.io.
Grafik Live Harga Molecules of Korolchuk IP-NFT(VITA-FAST)
Harga Molecules of Korolchuk IP-NFT(VITA-FAST) Hari Ini
Harga Molecules of Korolchuk IP-NFT(VITA-FAST) hari ini adalah Rp80,797.19, dengan volume perdagangan 24 jam sebesar Rp119.35M dan dengan begitu Molecules of Korolchuk IP-NFT(VITA-FAST) memiliki kapitalisasi pasar sebesar Rp80.79B, yang memberinya dominasi pasar sebesar +0%. Harga Molecules of Korolchuk IP-NFT(VITA-FAST) bergerak +0.32% dalam 24 jam terakhir.
Data Harga VITA-FAST
- Volume 24JRp119.35M
- All-Time High(ATH)Rp513,580.54
- Tinggi 24JRp85,075.66
- All-Time Low(ATL)Rp35,215.07
- Rendah 24JRp78,987.07
Info Kap Pasar VITA-FAST
- Kap PasarRp80.79B
- Fully Diluted ValuationRp80.79B
- Kap Pasar/FDV100%
- Sentimen PasarNetral
Pasokan VITA-FAST
- Pasokan Beredar1M VITA-FAST
- Total Pasokan1M VITA-FAST
- Pasokan Maks1M VITA-FAST
Tentang Molecules of Korolchuk IP-NFT(VITA-FAST)
Kontrak

0x6034e0d...6a1d33d36
Explorer
etherscan.io
Situs web
vitadao.com
Tag
What is the project about?
VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research.
1. What is the project about?
The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
2. What makes your project unique?
The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
3. History of your project.
The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies.
4. What’s next for your project?
The next steps involve screening third-generation compounds, conducting in vitro and in vivo mo